Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

National Recommendations for the Pharmacological Treatment of Hypertension

National Recommendations for the Pharmacological Treatment of Hypertension COMMENTARY National Recommendations for the Pharmacological Treatment of Hypertension Should They Be Revised? INCE PUBLICATION of the propriate for initial treatment. This channel blocker (nitrendipine, not Sixth Report of the latter recommendation was at vari- available in the United States) as Joint National Commit- ance with previous JNC (Joint Na- baseline therapy. The recommen- tee on Prevention, De- tional Committee on Detection, dations were also based on ad- tection, Evaluation, and Evaluation, and Treatment of High equate long-term safety data and the Treatment of High Blood Pressure Blood Pressure) reports and the demonstration of a high level of pa- (JNC VI) in the November 24, 1997, views of many physicians that mono- tient tolerability with diuretics and issue of the ARCHIVES, several long- therapy should be the approach fa- b-blockers. Although adverse ef- term morbidity and mortality trials vored in most cases. fects did occur with their use, the and several comparative medica- The JNC VI report noted that majority of treated patients re- tion studies have been published. It in special situations, specific drugs mained relatively free of symp- 3,4 is of interest to review the rationale should be chosen. For example, in toms. Finally, although cost of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

National Recommendations for the Pharmacological Treatment of Hypertension

Moser, Marvin
JAMA Internal Medicine , Volume 159 (13) – Jul 12, 1999
Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/national-recommendations-for-the-pharmacological-treatment-of-JnsyVu9DMq

References (22)

Publisher
American Medical Association
Copyright
Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.159.13.1403
Publisher site
See Article on Publisher Site

Abstract

COMMENTARY National Recommendations for the Pharmacological Treatment of Hypertension Should They Be Revised? INCE PUBLICATION of the propriate for initial treatment. This channel blocker (nitrendipine, not Sixth Report of the latter recommendation was at vari- available in the United States) as Joint National Commit- ance with previous JNC (Joint Na- baseline therapy. The recommen- tee on Prevention, De- tional Committee on Detection, dations were also based on ad- tection, Evaluation, and Evaluation, and Treatment of High equate long-term safety data and the Treatment of High Blood Pressure Blood Pressure) reports and the demonstration of a high level of pa- (JNC VI) in the November 24, 1997, views of many physicians that mono- tient tolerability with diuretics and issue of the ARCHIVES, several long- therapy should be the approach fa- b-blockers. Although adverse ef- term morbidity and mortality trials vored in most cases. fects did occur with their use, the and several comparative medica- The JNC VI report noted that majority of treated patients re- tion studies have been published. It in special situations, specific drugs mained relatively free of symp- 3,4 is of interest to review the rationale should be chosen. For example, in toms. Finally, although cost of

Journal

JAMA Internal Medicine – American Medical Association

Published: Jul 12, 1999

There are no references for this article.